Maplight Therapeutics (NASDAQ:MPLT) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Maplight Therapeutics (NASDAQ:MPLT) from a hold rating to a sell rating in a report released on Saturday.

MPLT has been the topic of a number of other research reports. Leerink Partners started coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set an “outperform” rating and a $30.00 target price for the company. Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th. Jefferies Financial Group initiated coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued a “buy” rating and a $32.00 price objective for the company. Stifel Nicolaus began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $28.00 target price on the stock. Finally, Morgan Stanley assumed coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued an “overweight” rating and a $34.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Maplight Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $31.80.

Maplight Therapeutics Stock Performance

MPLT opened at $17.56 on Friday. Maplight Therapeutics has a one year low of $12.24 and a one year high of $21.55. The company has a market capitalization of $796.70 million and a PE ratio of -0.47. The company’s 50 day simple moving average is $17.88.

Insider Activity at Maplight Therapeutics

In related news, Director Timothy John Garnett purchased 14,124 shares of Maplight Therapeutics stock in a transaction dated Tuesday, February 10th. The stock was purchased at an average cost of $17.89 per share, with a total value of $252,678.36. Following the transaction, the director owned 14,124 shares in the company, valued at approximately $252,678.36. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director George Pavlov acquired 10,658 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were bought at an average price of $17.48 per share, with a total value of $186,301.84. Following the completion of the purchase, the director directly owned 10,658 shares in the company, valued at $186,301.84. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 39,124 shares of company stock valued at $693,846 and have sold 74,612 shares valued at $1,368,065.

Institutional Trading of Maplight Therapeutics

Several hedge funds have recently modified their holdings of MPLT. Fcpm Iii Services B.V. bought a new stake in shares of Maplight Therapeutics in the 4th quarter valued at about $56,672,000. T. Rowe Price Investment Management Inc. purchased a new stake in Maplight Therapeutics during the fourth quarter valued at approximately $49,154,000. Goldman Sachs Group Inc. acquired a new stake in Maplight Therapeutics in the fourth quarter valued at approximately $34,026,000. Nan Fung Group Holdings Ltd purchased a new position in Maplight Therapeutics in the fourth quarter worth $17,060,000. Finally, 5AM Venture Management LLC purchased a new position in Maplight Therapeutics in the fourth quarter worth $16,687,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.